Biography for Tracy Staton
Tracy Staton is the editor of FiercePharma. She has been a freelance writer for five years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at email@example.com or find her on LinkedIn.
Articles by Tracy Staton
Johnson & Johnson has finally made a deal with the Justice Department. The Big Pharma giant agreed to pay $2.2 billion and plead guilty to a misdemeanor to wrap up a long-standing probe into its marketing of the antipsychotic drug Risperdal.
The FDA has asked drugmakers to recall several products with dosing systems or potency variations that could lead to dangerous overdoses.
We know Reckitt Benckiser is shopping its pharma unit. We also know that Shire is scouting for deals. Does it follow that Shire may bid on RB Pharma? Logically, yes. Practically? Maybe.
Drugmakers see contract reps as an easy-come, easy-go approach to marketing. Hire up when times are busy and new drugs rolling; staff down when drugs go off patent or the cost-cutting police come calling. But contract reps have rights, too--and that's why a former Eli Lilly sales person is suing the company.
Drugmakers can spread their copay discounts to a new group of patients: Obamacare's enrollees. It's a victory for the practice, which pharma companies use to woo patients to new brands or build loyalty for older drugs soon to go off patent.
GlaxoSmithKline bigwigs can breathe a sigh of relief, if a tentative one. The company probably won't face corruption charges in China, Reuters sources say. But Glaxo's local executives probably will.
The Swiss drugmaker is wading into research that could top the GLP-1 diabetes-fighting class by adding one of the drugs to another imitation hormone, GIP, for a combination treatment.
AstraZeneca has a new CFO to replace the departing Simon Lowth: Marc Dunoyer, who joined the company from GlaxoSmithKline earlier this year. He'll have plenty of work on his plate: The company's sales continue to slide on generic competition, it's in the middle of a cost-cutting plan and headquarters move, and more patent expirations are on their way.
In the aftermath of Teva CEO Jeremy Levin's departure announcement yesterday, media reports offer a few puzzle pieces that combine into one picture: Who in the world will the generics giant find to take on the job?